Figure 1From: Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries PH-specific medication at inclusion (% of patients). Medication for PH at time of inclusion (% of patients).Back to article page